Literature DB >> 35693079

The microbiome of lung cancer tissue and its association with pathological and clinical parameters.

Ock-Hwa Kim1,2, Bo-Yun Choi3, Dong Kwan Kim4, Na Hyun Kim1, Jin Kyung Rho5, Woo Jun Sul3, Sei Won Lee1.   

Abstract

Lung cancer is the primary cause of cancer-related deaths worldwide. Recently, although the microbiome has emerged as the key modulator of the carcinogenesis, it has not been evaluated in lung cancer. Here, we evaluated the microbial composition of lung cancer tissues according to the histologic type and genetic mutation, compared it with that of the adjacent normal lung tissues, and investigated the association between the lung microbiome and clinical parameters. We collected lung tissue samples from 162 patients with non-small cell lung cancer (NSCLC, 162 cancer and 54 adjacent normal tissues), surgically resected between January 2018 and December 2019, and analyzed their microbiome using 16S rRNA gene amplicon sequencing, the QIIME2 pipeline, and statistical analyses. NSCLC tissues had significantly lower alpha diversity than the normal tissues, and their microbial composition differed according to the histologic type and cancer genetic mutation. The genera Romboutsia, Novosphingobium, Acinetobacter, and Prevotella were significantly overrepresented in NSCLC tissues. Alpha diversity steadily declined from a normal to a more advanced stage, and microbial compositional differences were noted along with recurrence. Stenotrophomonas was the most predominant genus in the NSCLC tissues of patients with recurrence. The pathways related to the tricarboxylic acid cycle and L-glutamate and L-glutamine biosynthesis were predominant in adenocarcinoma, whereas those related to purine and pyrimidine nucleotide degradation and formaldehyde assimilation were predominant in squamous cell carcinoma. Our findings suggest that the altered lung cancer microbial composition might be associated with cancer initiation and/or progression. AJCR
Copyright © 2022.

Entities:  

Keywords:  Lung cancer; Stenotrophomonas; microbiome; normal lung tissue

Year:  2022        PMID: 35693079      PMCID: PMC9185621     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  34 in total

1.  The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival.

Authors:  Brandilyn A Peters; Richard B Hayes; Chandra Goparaju; Christopher Reid; Harvey I Pass; Jiyoung Ahn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-07       Impact factor: 4.254

Review 2.  The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy.

Authors:  Ariel G Ramírez-Labrada; Dolores Isla; Angel Artal; Maykel Arias; Antonio Rezusta; Julián Pardo; Eva M Gálvez
Journal:  Trends Cancer       Date:  2020-01-18

3.  Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects.

Authors:  Hai-Xia Liu; Li-Li Tao; Jing Zhang; Ying-Gang Zhu; Yu Zheng; Dong Liu; Min Zhou; Hui Ke; Meng-Meng Shi; Jie-Ming Qu
Journal:  Int J Cancer       Date:  2017-11-08       Impact factor: 7.396

Review 4.  Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer.

Authors:  Seyed Javad Moghaddam; Cesar E Ochoa; Sanjay Sethi; Burton F Dickey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-01-27

5.  Application of a neutral community model to assess structuring of the human lung microbiome.

Authors:  Arvind Venkataraman; Christine M Bassis; James M Beck; Vincent B Young; Jeffrey L Curtis; Gary B Huffnagle; Thomas M Schmidt
Journal:  MBio       Date:  2015-01-20       Impact factor: 7.867

Review 6.  The emerging role and targetability of the TCA cycle in cancer metabolism.

Authors:  Nicole M Anderson; Patrick Mucka; Joseph G Kern; Hui Feng
Journal:  Protein Cell       Date:  2017-07-26       Impact factor: 14.870

Review 7.  Glutamine Addiction and Therapeutic Strategies in Lung Cancer.

Authors:  Karolien Vanhove; Elien Derveaux; Geert-Jan Graulus; Liesbet Mesotten; Michiel Thomeer; Jean-Paul Noben; Wanda Guedens; Peter Adriaensens
Journal:  Int J Mol Sci       Date:  2019-01-10       Impact factor: 5.923

Review 8.  Microbiome dysbiosis in lung cancer: from composition to therapy.

Authors:  Ning-Ning Liu; Qiang Ma; Yang Ge; Cheng-Xiang Yi; Lu-Qi Wei; Jing-Cong Tan; Qiao Chu; Jing-Quan Li; Peng Zhang; Hui Wang
Journal:  NPJ Precis Oncol       Date:  2020-12-10

Review 9.  Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.

Authors:  Carmine Carbone; Geny Piro; Vincenzo Di Noia; Ettore D'Argento; Emanuele Vita; Miriam Grazia Ferrara; Sara Pilotto; Michele Milella; Giovanni Cammarota; Antonio Gasbarrini; Giampaolo Tortora; Emilio Bria
Journal:  Mediators Inflamm       Date:  2019-11-11       Impact factor: 4.711

Review 10.  Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms.

Authors:  Nana Xu; Lei Wang; Chenxi Li; Chao Ding; Cong Li; Wenting Fan; Chen Cheng; Bing Gu
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.